AAO Digital GUIDELINES Apps (free trial)

Diabetic Retinopathy

AAO GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/557414

Contents of this Issue


Page 19 of 19

Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Source American Academy of Ophthalmolog y Retina/Vitreous Panel. Preferred Practice Pattern ® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmolog y; 2014. Available at: www.aao.org/ppp. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at GuidelineCentral.com Copyright © 2015 All rights reserved AAODRET15043b Table 9. Side Effects and Complications of Treatment for Diabetic Retinopathy Treatment Side Effect/Complication Focal laser photocoagulation for diabetic macular edema • Possible transient initial decrease in central vision • Paracentral scotomas if laser burns have been placed close to the fovea, especially large or confluent burns • Permanent central scotoma from inadvertent foveal burns • Expansion of laser scar area (over many years) Panretinal photocoagulation (scatter) for severe NPDR or PDR • Transient central vision loss from macular edema • Peripheral visual field constriction with delayed dark adaptation • Vitreous hemorrhage if neovascularization is present • Reduced or compromised accommodation • Pupillary dilation (mydriasis) Vitrectomy • Recurrent vitreous hemorrhage • Retinal tear or detachment • Vision loss • Infectious endophthalmitis • Cataract Intravitreal injections • Cataract • Elevated IOP (i.e., corticosteroids) • Infectious endophthalmitis • Noninfectious inflammatory reactions • Possible systemic effect from intravitreal medication • Increased retinal traction IOP, intraoclar pressure; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy

Articles in this issue

Links on this page

Archives of this issue

view archives of AAO Digital GUIDELINES Apps (free trial) - Diabetic Retinopathy